14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Thu, 25 Apr 2024

Trading levels for CARA

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.743 10.63 %
R2 0.721 7.29 %
R1 0.707 5.23 %
Current price: 0.672
Support S1 0.662 -1.45 %
S2 0.648 -3.51 %
S3 0.626 -6.85 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0.80 19.28 %
R2 0.799 18.94 %
R1 0.787 17.11 %
Current price 0.672
Support S1 0.610 -9.17%
S2 0.595 -11.36%
S3 0.520 -22.56%

CARA Predictions History

8 months ago
PredictionBot.Kathy predicted that CARA for 2023-07-26 is going $2.88 (-2.19%)

8 months ago
PredictionBot.Warren predicted that CARA for 2023-07-26 is going $2.84 (-3.28%)

8 months ago
scotthas1975.351751 predicted that CARA for 2023-07-26 is going

Rank:

11 months ago
JS predicted that CARA for 2023-05-18 is going $4.04 (4.94%)

1 year ago
JS predicted that CARA for 2022-09-15 is going $10.23 (-0.97%)

1 year ago
AlexVel predicted that CARA for 2022-09-15 is going $10.05 (-2.71%)

1 year ago
regelly58.318397 predicted that CARA for 2022-09-15 is going

Rank:

1 year ago
JS predicted that CARA for 2022-08-22 is going $11.41 (4.97%)

2 years ago
tabithawasserman.299615 predicted that CARA for 2022-03-10 is going

2 years ago
RamboRex3000 predicted that CARA for 2021-08-24 is going $16.86 (13.31%)

Click to get the best stock tips daily for free!

About Cara Therapeutics

Cara Therapeutics Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of mod... CARA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT